Literature DB >> 2962780

CD4 and CD8 subsets defined by dual-color cytofluorometry which distinguish symptomatic from asymptomatic blood donors seropositive for human immunodeficiency virus.

H E Prince1, L Arens, S H Kleinman.   

Abstract

As part of a larger study to characterize immune alterations in blood donors seropositive for human immunodeficiency virus (HIV), we measured subsets of CD4 (T helper/inducer) and CD8 (T suppressor/cytotoxic) cells by 2-color cytofluorometry. Alterations observed in asymptomatic seropositive donors (ASP) included: 1) decreased mean levels of Leu 8+ CD4 cells, although the proportion of Leu 8+ cells within the CD4 population was unchanged; 2) a selective increase in Leu 8- CD8 and Leu 18- CD8 cell levels; and 3) increased levels of both CD8 subsets defined by Leu 7, Leu 17, or HLA-DR expression. Alterations observed in symptomatic seropositive donors (SSP) were: 1) a further decrease in Leu 8+ CD4 cell levels, with a decrease in the proportion of Leu 8+ CD4 cells; 2) decreased levels of both Leu 18- and Leu 18+ CD4 subsets; 3) selective increases in Leu 8- and Leu 18- CD8 cell levels; and 4) increases in Leu 7+ CD8, Leu 17+ CD8, and HLA-DR+ CD8 subsets but not the reciprocal negative CD8 subsets. Thus, changes merely reflective of HIV infection included decreased levels of Leu 8+ CD4 cells and increased levels of Leu 8- CD8, Leu 18- CD8, Leu 7+ CD8, Leu 17+ CD8, and HLA-DR+ CD8 cells. Development of symptoms were associated with a further, preferential loss of Leu 8+ CD4 cells, proportional losses of both CD4 subsets defined by Leu 18 expression, and a return to normal levels of Leu 7- CD8, Leu 17- CD8, and HLA-DR- CD8 cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2962780

Source DB:  PubMed          Journal:  Diagn Clin Immunol        ISSN: 0895-0458


  9 in total

Review 1.  Modern flow cytometry: a practical approach.

Authors:  James W Tung; Kartoosh Heydari; Rabin Tirouvanziam; Bita Sahaf; David R Parks; Leonard A Herzenberg; Leonore A Herzenberg
Journal:  Clin Lab Med       Date:  2007-09       Impact factor: 1.935

2.  Preferential loss of Leu 8-, CD45R, HLA-DR+ CD8 cell subsets during in vitro culture of mononuclear cells from human immunodeficiency virus type I (HIV)-seropositive former blood donors.

Authors:  H E Prince; C D Czaplicki
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

3.  Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire.

Authors:  P Ondoa; S Koblavi-Dème; M-Y Borget; M L Nolan; J N Nkengasong; L Kestens
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

4.  T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.

Authors:  M Levacher; S Tallet; M C Dazza; E Dournon; B Rouveix; J J Pocidalo
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  Lysis of CD4+ lymphocytes by non-HLA-restricted cytotoxic T lymphocytes from HIV-infected individuals.

Authors:  M D Grant; F M Smaill; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

6.  Anti-lymphocyte antibodies in plasma of HIV-1-infected patients preferentially react with MHC class II-negative T cells and are linked to antibodies against gp41.

Authors:  C Müller; S Kukel; K E Schneweis; R Bauer
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

7.  Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection.

Authors:  G Vanham; L Kestens; G Penne; C Goilav; P Gigase; R Colebunders; M Vandenbruaene; J Goeman; G van der Groen; J L Ceuppens
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

8.  The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value.

Authors:  M Levacher; F Hulstaert; S Tallet; S Ullery; J J Pocidalo; B A Bach
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

9.  Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.

Authors:  Pin Wang; Luanluan Wang; Long Chen; Xiulian Sun
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.